Pharma Press Releases

Keep up to date with the latest technological developments happening across the Pharmaceutical industry. Our press releases can help you boost your online reach and exposure worldwide. Our Press releases provides information on the latest research in pharma.

60 years of Packaging Excellence - Syntegon’s Schiedam site celebrates anniversary and long heritage

Monday, September 28, 2020

Syntegon Technologys Schiedam site is celebrating over half a century of market presence In October the companys Dutch site turns Today a marketleading provider of horizontal flow wrappers infeed and distribution systems the current Syntegon Packagi...

Etihad Cargo Reinforces Pharmaceutical Shipment Expertise With PharmaLife Launch

Monday, September 28, 2020

Etihad Cargo the cargo and logistics arm of Etihad Aviation Group has reinforced its pharmaceutical logistics expertise with the launch of PharmaLife a specialised pharma and healthcare product which replaces the carriers TempCheck productb

FDA Grants IND Approval for Phase II Clinical Trial Using Stemedica's itMSC Therapy for COVID-19 Patients

Monday, September 28, 2020

Stemedica Cell Technologies Inc has received US Food and Drug Administration FDA Investigational New Drug IND approval for A Phase II MultiCenter Randomized DoubleBlind PlaceboControlled Study to Assess the Safety Tolerability and Preliminary Efficac...

FDA Approves Nucala as the First and Only Biologic Treatment for Hypereosinophilic Syndrome (HES)

Saturday, September 26, 2020

GlaxoSmithKline plc announced the US Food and Drug Administration FDA has approved Nucala mepolizumab for the treatment of adult and pediatric patients aged years and older with Hypereosinophilic Syndrome HES for six months without an identifiable...

FDA Grants AT-007 Pediatric Rare Disease Designation and Orphan Designation for Treatment of PMM2-CDG

Friday, September 25, 2020

Applied Therapeutics Inc a clinicalstage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need announced today that the US Food and Drug Administration F...

Millendo Therapeutics Announces Initiation of First-in-Human Clinical Trial of MLE-301, a Selective NK3R Antagonist

Friday, September 25, 2020

Millendo Therapeutics Inc a clinicalstage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases with significant unmet needs announced dosing of the first subject in a Phase clinical trial evaluating the s...

Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s Investigational Gene Therapy for Wilson Disease

Thursday, September 24, 2020

Vivet Therapeutics Vivet a privately held gene therapy biotech company dedicated to developing treatments for inherited liver disorders with high unmet medical need and Pfizer Inc NYSE PFE announced today that they have entered into a manufacturing a...

Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's COVID-19 Vaccine Candidate

Thursday, September 24, 2020

Johnson Johnson announced the launch of its largescale pivotal multicountry Phase trial ENSEMBLE for its COVID vaccine candidate JNJ being developed by its Janssen Pharmaceutical Companies The initiation of the ENSEMBLE trial follows positive inter...

Gyroscope Therapeutics Granted FDA Fast Track Designation for GT005, an Investigational Gene Therapy for Dry Age-Related Macular Degeneration

Wednesday, September 23, 2020

Gyroscope Therapeutics Limited a clinicalstage retinal gene therapy company announced that the US Food and Drug Administration FDA has granted Fast Track designation to GT for the treatment of geographic atrophy GA secondary to dry agerelated macular...

Genetics Research and Oxford Nanopore Technologies Sign Non-Exclusive Licensing Agreement for Genetics Research’s Patented DNA Negative Enrichment Technology Platform

Wednesday, September 23, 2020

Genetics Research LLC GR a privatelyheld company developing a portfolio of novel and proprietary CRISPRassociated technologies for targeted DNA enrichment announced today that it has licensed certain of its patents relating to this technology to Oxfo...

City of Hope Enters Licensing Agreement With Chimeric to Develop Its Pioneering Chlorotoxin CAR T Cell Therapy

Tuesday, September 22, 2020

City of Hope a worldrenowned independent research and treatment center for cancer diabetes and other lifethreatening diseases announced that it has licensed intellectual property relating to its pioneering chlorotoxin chimeric antigen receptor CLTXCA...

PharmAbcine expands partnership with Samsung Biologics for PMC-403

Tuesday, September 22, 2020

PharmAbcine Inc entered into a strategic partnership with Samsung Biologics for the development and manufacturing of PMC pipeline the next generation therapeutic antibody candidate to treat neovascular disorders Samsung will provide the full scope of...

Bristol Myers Squibb Completes Acquisition of Forbius

Tuesday, September 22, 2020

Bristol Myers Squibb announced that it has successfully completed its transaction to acquire Forbius for their TGFbeta program including its lead investigational asset AVID currently in Phase for oncology and fibrosis

Genocea Announces FDA Acceptance of GEN-011 IND Application

Tuesday, September 22, 2020

Genocea Biosciences Inca biopharmaceutical company developing nextgeneration neoantigen immunotherapies today announced that the US Food and Drug Administration FDA has accepted the companys Investigational New Drug IND Application for GEN an adoptiv...

Preparation products of Yiling Pharma approved by FDA for launch in the US market

Monday, September 21, 2020

Yiling Pharmaceutical Co Ltd announced on Friday that it had received the approvals of the Abbreviated New Drug Applications ANDA about Lisinopril Tablets and Acyclovir Capsules from United States Food and Drug Administration hereinafter referred to...

Crinetics Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for CRN04777 for the Treatment of Congenital Hyperinsulinism

Monday, September 21, 2020

Crinetics Pharmaceuticals Inc a clinical stage pharmaceutical company focused on the discovery development and commercialization of novel therapeutics for rare endocrine diseases and endocrinerelated tumors today announced that the US Food and Drug A...

Axsome Therapeutics Announces Expedited Development of AXS-12 for the Treatment of Narcolepsy Based on FDA Breakthrough Therapy Meeting

Monday, September 21, 2020

Axsome Therapeutics Inc a biopharmaceutical company developing novel therapies for the management of central nervous system CNS disorders today announced that the development plan for AXS for the treatment of narcolepsy has been expedited following a...

Verzenio® Significantly Reduced the Risk of Cancer Recurrence by 25% for People with HR+, HER2- High Risk Early Breast Cancer

Monday, September 21, 2020

Eli Lilly and Companyannounced Verzenio abemaciclib in combination with standard adjuvant endocrine therapy ET significantly decreased the risk of breast cancer recurrence by percent compared to standard adjuvant ET alone for people with hormone rec...

Precision BioSciences and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate PBCAR269A

Monday, September 21, 2020

Precision BioSciences Inc a clinical stage biotechnology developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS genome editing platform and SpringWorks Therapeutics Inc Nasdaq SWTX a clinicalstage biopharmaceutical company f...

Novartis Kisqali® receives the highest rating of any CDK4/6 inhibitor on the ESMO Magnitude of Clinical Benefit Scale

Monday, September 21, 2020

Novartis proudly announces that Kisqali ribociclib has achieved a score of five out of five on the European Society for Medical OncologyMagnitude of Clinical Benefit Scale ESMOMCBS for firstline premenopausal patients with hormone receptor positive h...

Takeda establishes new cell drug manufacturing facility for research and development to support expansion of next-generation clinical programs

Saturday, September 19, 2020

Takeda Pharmaceutical Company Limited in Boston Massachusetts to expand its capacity to manufacture cell medicine Announced that it has built a new squarefoot cell medicine manufacturing facility for R D within its R D base

Elicio Therapeutics and Moffitt Collaborate to Study AMP-CD19 in Combination with CD19 CAR T Cells

Friday, September 18, 2020

Elicio Therapeutics a next generation immunooncology company announced that it has established a collaboration with the Moffitt Cancer Center to characterize combination therapies pairing Elicios CD Amphiphile and a universal FITC Amphiphile with CD...

Zynerba Pharmaceuticals Receives Orphan Drug Designation for Cannabidiol for the Treatment of 22q11.2 Deletion Syndrome

Friday, September 18, 2020

Zynerba Pharmaceuticals Inc the leader in innovative pharmaceuticallyproduced transdermal cannabinoid therapies for rare and nearrare neuropsychiatric disorders announced that the US Food and Drug Administration has granted orphan drug designation fo...

Junshi Biosciences Receives Orphan Drug Designation from the U.S. FDA for Toripalimab for the Treatment of Soft Tissue Sarcoma

Friday, September 18, 2020

Junshi Biosciences a leading innovationdriven biopharmaceutical company dedicated to the discovery development and commercialization of novel therapies announced today that the US Food and Drug Administration FDA has recently granted Orphan Drug desi...

AlloVir Announces the FDA Clearance of Investigational New Drug Application (IND) for ALVR109 for the Treatment of High-Risk COVID-19 Patients

Friday, September 18, 2020

AlloVir a late clinicalstage cell therapy company announced that the US Food and Drug Administration FDA has cleared the Investigational New Drug application IND for ALVR an allogeneic offtheshelf virusspecific T cell therapy candidate designed to ta...

Zynerba Pharmaceuticals Receives Orphan Drug Designation for Cannabidiol for the Treatment of 22q11.2 Deletion Syndrome

Friday, September 18, 2020

Zynerba Pharmaceuticals Inc the leader in innovative pharmaceuticallyproduced transdermal cannabinoid therapies for rare and nearrare neuropsychiatric disorders today announced that the US Food and Drug Administration has granted orphan drug designat...

Moderna and Vertex Establish New Collaboration to Treat Cystic Fibrosis Using Gene Editing

Thursday, September 17, 2020

Moderna Incand Vertex Pharmaceuticals Incorporated announced a new strategic research collaboration and licensing agreement aimed at the discovery and development of lipid nanoparticles LNPs and mRNAs for the delivery of geneediting therapies for the...

Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH)

Thursday, September 17, 2020

Moderna Inc a biotechnology company pioneering messenger RNA mRNA therapeutics and vaccines to create a new generation of transformative medicines for patients and Chiesi Farmaceutici SpA an international researchfocused healthcare group Chiesi Group...

LamKap Bio Group and Lonza Collaborate to Manufacture Bispecific Antibodies for Cancer Treatment

Thursday, September 17, 2020

LamKap Bio Group a biotechnology group focused on the research development and manufacturing of tumortargeted antibodybased therapies and Lonza announced today that the companies have a development and manufacturing collaboration in place to support...

Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development

Thursday, September 17, 2020

Dyadic International Inc a global biotechnology company focused on further applying its proprietary C gene expression platform to accelerate development lower production costs and improve the performance of biologic vaccines and drugs at flexible com...